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Introduction: Adult T-cell leukemia/lymphoma (ATL) responds poorly to conventional chemotherapy, but allogeneic
stem cell transplantation (allo-SCT) may improve disease prognosis. Herein, we report a female patient with human
T-cell leukemia virus type I (HTLV-I)-associated myelopathy (HAM)-like myelopathy following allo-SCT for ATL.
Case report: She developed crural paresis 14 months after allo-SCT. Initially, she was diagnosed with central nervous
system (CNS) relapse of ATL and treated with intrathecal injection and whole brain and spine irradiation. Her symptoms
recurred 5 months later, when a cerebrospinal fluid (CSF) specimen showed increased CD4 + CXCR3 + CCR4+ cell
numbers and levels of neopterin and CXCL10 (IP-10).
Discussion: These results suggest the possible involvement of a certain immunological mechanism such as HAM in
her symptoms, irrespective of the lack of anti-HTLV-I antibody in her CSF. Because a definitive diagnosis of CNS
manifestation of ATL is sometimes difficult, multi-modal laboratory data are required for differential diagnosis.
Keywords: Adult T-cell leukemia/lymphoma; Post-transplant myelopathy; HTLV-I-associated myelopathy (HAM);
Neopterin; CXCL10 (IP-10)Introduction
Human T-cell leukemia virus type I (HTLV-I) was the
first retrovirus identified in humans, isolated from a
patient with cutaneous lymphoma (Poiesz et al. 1980).
HTLV-I is the cause of not only adult T-cell leukemia/
lymphoma (ATL) (Uchiyama et al. 1977; Hinuma et al.
1981) but also HTLV-I-associated myelopathy (HAM)/
tropical spastic paraparesis (TSP) (Osame et al. 1986),
HTLV-I-associated uveitis (HU) (Ohba et al. 1989;
Mochizuki et al. 1992) and infective dermatitis (McGill
et al. 2012; de Oliveira et al. 2010).
ATL is one of the most intractable T-cell malignancies,
and it responds poorly to conventional chemotherapy,
with a median survival time (MST) of approximately* Correspondence: toyotaka@ims.u-tokyo.ac.jp
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in any medium, provided the original work is p8 months (Shimoyama et al. 1988). Among such treat-
ments, modified LSG-15 (mLSG-15) has shown the best
results; in a previous study, the progression free survival
(PFS) at 1 year among patients treated with mLSG-15 was
28% and the overall survival (OS) at 3 years was 24%
(Tsukasaki et al. 2007). However, the improvement in
survival time by mLSG-15 treatment is not satisfactory.
Allo-HSCT is a promising treatment option to cure ATL
because it may improve disease prognosis (Utsunomiya
et al. 2001; Kami et al. 2003).
Herein, we describe a case of HAM-like myelopathy that
was difficult to distinguish from central nervous system
(CNS) relapse of ATL following allogeneic peripheral blood
stem cell transplantation. This case report suggests that
there might be immunological myelopathy after HSCT. In
the present case, flow cytometric analysis of the cells in
cerebrospinal fluid (CSF) was helpful to differentiate it
from CNS relapse of ATL.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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A 63-year-old female patient recognized cervical lymph
nodes swelling in October 2010. Lactate dehydrogenase
(LDH) and serum corrected calcium levels kept within
normal limit, but soluble interleukin-2 receptor (sIL-2R)
elevated significantly at the initial visit (Table 1). Diag-
nostic imaging by computed tomography (CT) revealed
systemic lymphadenopathies (cervical, axial, mediastinal,
abdominal and mesenteric lymphadenopathy) before the
following chemotherapy. Although appetite loss and ab-
dominal distention were added with lymphadenopathy,
any other abnormal finding of physical examination
could not be detected. Her ECOG performance status
was grade 1 before chemotherapy. She received cervical
lymph node biopsy and pathological findings of cervical
lymph node revealed T cell lymphoma compatible, and
HTLV-I provirus DNA analysis (Southern blot) revealed
monoclonal integration. Abnormal lymphocytes were not
detected in peripheral blood (PB) and HTLV-I provirus
DNA analysis of PB did not show monoclonal integration.
She was diagnosed as ATL (lymphoma type). She has past
histories of glaucoma and pulmonary cryptococcosis.
None of ATL patient was in her family.
She was referred to our hospital and received four ses-
sions of mLSG-15 therapy in our hospital. Prophylactic
intrathecal injection was performed twice, during
chemotherapy and before allogeneic stem cell trans-
plantation. No meningeal involvement of ATL cells was
detected at that time. She went into complete remission
(Response criteria for adult T cell leukemia-lymphoma
from an international consensus meeting (Tsukasaki et al.
2009)) in April 2011. She received following allogeneic per-
ipheral blood stem cell transplantation (allo-PBSCT) in the
National Cancer Center Hospital (Tokyo, Japan) (Figure 1).








RBC 423 × 104/μl Cre
Hb 13.2 g/dl Na
Hct 39.0% K
MCV 92.2 fl Cl
MCH 31.2 pg Corrected Ca
MCHC 33.8%
Plt 21.9 × 104/μlfludarabine (30 mg/m2 per day for 5 days) plus busulfan
(3.2 mg/kg per day for 2 days) and only cyclosporine A
(CyA) was used for GVHD prophylaxis. Transplanted
CD34-positive cells were 2.67 × 106/kg and rapid engraft-
ment was achieved. Grade III (gastrointestinal tract and
skin) acute graft-versus-host disease (GVHD) was observed
1 month after transplantation, but it improved after
treatment with methylpredonisolone (mPSL) (1 mg/kg).
No chronic GVHD was observed. CyA was tapered
gradually and discontinued 9 months after transplantation,
in February 2012. After that point, only 5 mg/day predoni-
solone (PSL) was continued.
In July 2012 (14 months after allo-PBSCT), the patient
developed hemiparesis of the left side. Although left
upper-limb paresis improved, lower-extremity paresis
progressed to paraplegia. Magnetic resonance imaging
(MRI) revealed multiple high-intensity lesions in T2-
weighted images of the medulla oblongata, cervical
spinal cord, and thoracic spinal cord (Figure 2A), and a
CSF specimen showed increased cell counts (Figure 3).
Morphologically, typical ATL cells such as flower cells
were not detected in CSF, but abnormal small to middle
size lymphocytes indistinguishable from ATL cells
increased. She was diagnosed as CNS relapse of ATL,
and received mPSL pulse, intrathecal injection of MTX
15 mg + Ara-C 40 mg + PSL 20 mg, and irradiation of
the whole brain and spine. Following these treatments,
the paraplegia improved gradually to such a degree that
she could walk with a walker. During the course of these
treatments, she was complicated by neurogenic bladder
dysfunction, and diabetes insipidus.
In January 2013 (20 months after allo-PBSCT), she
again developed left lower-limb weakness, which gradually
progressed. She was admitted to our hospital in February
2013. On admission, neurological examination revealedOctober 2010
67 IU/L CRP 0.06 mg/dl
72 IU/L sIL-2R 5802 U/ml
215 IU/L
277 IU/L HTVL-I Ab (+)
46 IU/L HBs-Ag (−)
3.5 mg/dl HBs-Ab (−)
15.6 mg/dl HBc-Ab (−)
0.58 mg/dl HCV-Ab (−)
142.4 mEq/L HIV-Ab (−)
4.2 mEq/L TPHA (−)
103.8 mEq/L
9.9 mg/dl
Figure 1 Clinical course from conventional chemotherapy (mLSG-15) to allogeneic peripheral blood stem cell transplantation. The patient
received four sessions of mLSG-15 therapy and achieved complete remission (CR) before receiving allo-PBSCT.
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reflex such as Babinski and Chaddock reflex in bilateral
lower-limb. Thermal hypoalgesia under right Th4 and left
Th6 dermatome was detected, but tactile sense was intact.
She was accompanied with bladder dysfunction and severe
constipation. Brain and spinal MRI revealed a residualOnset(July.2012) Recurrence(FeA B
Figure 2 MRI findings. A) At the onset of neurogenic disorder in July 201
medulla oblongata, cervical spinal cord, and thoracic spinal cord were reve
the residual lesion in the thoracic spinal cord improved.spinal lesion at Th3-7 (Figure 2B). The cell numbers in
CSF did not increase, but myelin basic protein (MBP) level
was elevated (Figure 4B). Morphologically, ATL cells could
not be detected in CSF. Flow cytometric analysis to deter-
mine the specific immunophenotype of CD4+ lymphocytes
in CSF revealed an expansion of the CD4+CXCR3+CCR4+b.2013) Posreatment(June.2013)C
2. Multiple high-intensity lesions in T2-weighted images (T2WI) of the
aled. B) Residual high-intensity lesion in Th3-7. C) Following treatment,
Figure 3 Clinical course after onset of the neurogenic disorder. The patient developed paraplegia 14 months after allo-PBSCT. Neurological
findings were partially relieved following treatment with a high dose of mPSL accompanied by intrathecal injection of MTX + Ara-C + PSL and
irradiation of the whole brain and spine. Three months later, her neurological deficit worsened again. Ultimately, her neurological disorder
improved after treatment with a high dose of steroid.
Figure 4 CSF findings. A) Flow cytometric analysis of CSF. Before treatment, the CD4 + CXCR3 + CCR4+ cell population was predominantly elevated.
Following treatment, it decreased and the CD4 + CXCR3 + CCR4- cell population increased. B) Neopterin and CXCL10 (IP-10) concentrations in CSF.
Before treatment, both neopterin and CXCL10 (IP-10) concentrations were significantly elevated. Following treatment, both biomarkers decreased to
within the range of the therapeutic goal for HAM patients.
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relapse of ATL but was consistent with HAM (Natsumi
et al. 2014). Furthermore, both the neopterin and CXCL10
(IP-10) concentrations in the CSF were significantly elevated
(Figure 4B), although lower than those associated with
aggressive HAM (14). Notably, the case was insufficient to
fulfill the diagnostic criteria for HAM (Mitsuhiro 1990)
because HTLV-I antibody (PA method) was negative in CSF.
Bacterial, fungal, and tuberculous encephalomyelopathies
were excluded because no increase in cell numbers and no
decline in glucose concentration in CSF were observed.
Real-time polymerase chain reaction (PCR) testing for
CMV, EBV, HSV, VZV, HHV-6, and JC virus in CSF
showed negative results.
Serum soluble interleukin-2 receptor (sIL-2R) level
was slightly elevated (Table 2), but significantly lower
compared with that at the onset of ATL.
Not all of the results necessarily corresponded to CNS
relapse of ATL, although we could not exclude it. We
treated her with mPSL pulse and intrathecal injection of
MTX + Ara-C + PSL. After one course of mPSL pulse,
her crural paresis improved dramatically to such a degree
that she could pull up to standing after a few days. Al-
though she was given intrathecal injections four times
weekly, her crural paresis was gradually exacerbated and
progressed to paralysis. mPSL pulse was performed again,
but the effect was limited.
We examined her CSF again but there was no increase
in cells, and ATL cells could not be detected by micro-
scopic examination. Furthermore, the MRI findings im-
proved over time (Figure 2C), although her neurological
findings worsened and HTLV-I proviral DNA could not
be detected repeatedly in peripheral mononuclear cells
(PBMCs) after allo-PBSCT. No evidence of relapsed
ATL could be found and we continued 5 mg/day PSL






Abnormal Ly 1.0% TP
RBC 302 × 104/μl Alb
Hb 9.5 g/dl BUN
Hct 29.4% Cre
MCV 97.4 fl Na
MCH 31.5 pg K
MCHC 32.3% Cl
Plt 12.0 × 104/μl Corrected CaThe results of CSF analysis in May 2013 showed the fol-
lowing improvements. In flow cytometric analysis, the
CD4 +CXCR3 +CCR4+ cell population had decreased
and the normal CD4 + CXCR3 + CCR4- cell population
had increased. Both neopterin and CXCL10 (IP-10) had
decreased to within the range of the therapeutic goal for
HAM patients (Figure 4A,B). Her paralysis improved
gradually and steadily only by rehabilitation, to such a de-
gree that she could walk when holding onto parallel bars.
Discussion
ATL with CNS involvement may occur during systemic
progression of the disease and its frequency is estimated to
be 10–25% (Kitajima et al. 2002). However, cases of CNS
relapse without peripheral blood and lymph nodes of ATL
have been reported (Marshall et al. 1998; Dungerwalla et al.
2005). In flow cytometric analysis of CSF of ATL patients,
the CD4 +CXCR3-CCR4+ cell population is elevated.
However, in the current case, the CSF fluid analysis
revealed expansion of the CD4 +CXCR3 +CCR4+ cell
population, which is consistent with HAM (Natsumi et al.
2014). Sato T et al. (Sato et al. 2013) reported increased
neopterin and CXCL10 (IP-10) in HAM patients, and they
were valuable biomarkers for disease progression of HAM.
The neopterin and CXCL10 (IP-10) concentration in CSF
paralleled the disease activity of HAM. The cut-off concen-
trations of neopterin and CXCL10 in HAM/TSP patients
compared to HTLV-I infected non-HAM subjects are less
than 5 pmol/mL and 200 pg/ml, respectively, and the
CXCL10 (IP-10) concentration in the CSF of HAM patients
with rapid progression is usually more than 5,000 pg/mL
(Yamono, Y., personal communication). In the current case,
we could not make a diagnosis of HAM because the CSF
was negative for HTLV-I antibody in repeated examina-
tions. Although the immunosuppressive status after allo-
PBSCT might contribute, serum immunoglobulin levelsary 2013
15 IU/L CRP 0.24 mg/dl
33 IU/L IgG 1390 mg/dl
199 IU/L IgA 51 mg/dl
453 IU/L IgM 352 mg/dl
87 IU/L
6.7 mg/dl HTVL-I Ab (+)
3.5 mg/dl HBs-Ag (−)
9.8 mg/dl HBs-Ab (−)
0.56 mg/dl HBc-Ab (−)
133 mEq/L HCV-Ab (−)
4.0 mEq/L HIV-Ab (−)
96 mEq/L
10.5 mg/dl
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(Table 2) and there is not enough evidence to indicate false
negative. In any inflammatory diseases of CNS, CXCR3+
cells but not CCR4+ cells were generally found in CSF
(Misu et al. 2001). However, CXCR3 +CCR4+ double posi-
tive cells existed in her CSF. It was unlikely that CXCR3 +
CCR4+ double positive cells emerged into CSF in nonspe-
cific inflammatory condition. Given her background, we
supposed these CCR4+ cells were HTLV-I infected cells,
but the number of these cells was insufficient to measure
HTLV-I viral load.
In the current case, neither CSF data nor clinical
course consisted with CNS relapse of ATL. In case of
ATL patients, CXCR3-CCR4+ T cell lymphocytes popula-
tion expanded. Therapeutic effect was obtained from
mPSL pulse rather than intrathecal injection. Further-
more, disease progression in the typical case of CNS re-
lapse of ATL was more aggressive. We concluded some
inflammatory condition caused by these HTLV-I infected
cells may have developed HAM-like myelopathy.
CNS GVHD remains a controversial entity and it is
difficult to establish an unequivocal diagnosis. Yet a few
cases have been reported, who were suspected of CNS
GVHD from brain biopsy or autopsy, their CSF showed
predominant T-lymphocyte infiltration of donor origin
(Kamble et al. 2007). In the current case, brain or spinal
cord biopsy was not performed, and chimerism analysis
of T cells in CSF was difficult because of the full-match
HLA and sex-matched PBSCT. The number of T cells in
CSF was insufficient to analyze chimerism using the short
tandem repeat (STR) method. Neopterin (Niederwieser
et al. 1984; Hempel et al. 1997) and CXCL10 (IP-10)
(Mapara et al. 2006) levels in serum increase significantly
in patients with active GHVD, but the levels in CSF are un-
known. The possibility of active CNS GVHD could not be
completely excluded. Both CXCR3 and CCR4 expression
of T cells infiltrated in the CNS in patients with active CNS
GVHD is unknown. It was no wander that CXCR3+ cells
in CSF were found in nonspecific inflammatory condition
such as CNS GVHD, but unlikely that CCR4+ cells were.
The patient’s neurological dysfunction seemed to fluctu-
ate in parallel with the serum concentration of soluble
interleukin-2 (sIL-2R) receptor (Figure 3). However, in-
creased sIL-2R occurs not only with ATL relapse but also
with HAM (Matsumoto et al. 1990), GVHD (Kami et al.
2000), and inflammatory neurogenic disorders caused by
immunologic T-cell responses (Maier et al. 2009). Thus, it
is difficult to make a definite diagnosis based on elevated
sIL-2R alone.
In conclusion, we report a case with myelopathy without
ATL relapse in the CNS. Flow cytometric analysis is help-
ful to differentiate immune-mediated encephalopathy or
myelopathy from CNS relapse of ATL. If we encountered
the patients suspected of CNS relapse of ATL, we shouldconsider the possibility of inflammatory condition caused
by HTLV-I infected cells. Further analysis of pathology are
warranted.
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